Mitra Ashoke, Araga Mako, Aher Abhay, Xu Jay, Shanga Gilbert, Franks Billy, Petruschke Richard
Haleon, Warren, NJ 07059, USA.
Haleon, 3811 LP Amersfoort, The Netherlands.
Healthcare (Basel). 2025 Apr 30;13(9):1032. doi: 10.3390/healthcare13091032.
The objective of the current post hoc analysis is to evaluate whether the combination of acetaminophen, aspirin, and caffeine (AAC) is more effective than placebo in relieving the pain intensity for and improving the quality-of-life (QoL) of subjects with menstrual migraine (MM). This analysis evaluated the impact of AAC (n = 85) versus placebo (n = 100) in relieving the pain intensity for and improving the QoL of subjects with MM during baseline and at 0.5, 1, 2, 3, 4, and 6 h post treatment. Subjects reported their pain intensity using a 4-point scale and QoL using a 5-point scale. A lower score indicates reduced pain intensity and improved QoL. A statistically significant difference between the AAC and placebo groups ( ≤ 0.001) was observed in pain relief after 1 h (40% vs. 14%), 2 h (56.5% vs. 24%), 3 h (63.5% vs. 31%), 4 h (65.9% vs. 34%), and 6 h (64.7% vs. 31%) post treatment. Similarly, a significantly higher proportion of subjects reported improved QoL at 1 h (48.2% vs. 28.0%; ≤ 0.005), 2 h (61.2% vs. 40.0%; ≤ 0.005), 3 h (68.2% vs. 44.0%; ≤ 0.001), 4 h (67.9% vs. 39.0%; ≤ 0.001), and 6 h (64.3% vs. 37.0%; ≤ 0.001) post treatment. The mean pain intensity and QoL scores reduced, while the relative pain intensity and QoL (difference between the AAC and placebo groups) increased with time and was sustained for 6 h. The rapid onset and sustained effect of AAC make it a potential option for managing headaches and other symptoms, and to improve the QoL of subjects with MM.
本次事后分析的目的是评估对乙酰氨基酚、阿司匹林和咖啡因组合（AAC）在缓解月经性偏头痛（MM）患者的疼痛强度及改善其生活质量（QoL）方面是否比安慰剂更有效。该分析评估了AAC组（n = 85）与安慰剂组（n = 100）在基线期以及治疗后0.5、1、2、3、4和6小时对MM患者疼痛强度的缓解作用及生活质量的改善情况。患者使用4分制报告疼痛强度，使用5分制报告生活质量。分数越低表明疼痛强度降低且生活质量改善。在治疗后1小时（40%对14%）、2小时（56.5%对24%）、3小时（63.5%对31%）、4小时（65.9%对34%）和6小时（64.7%对31%），AAC组和安慰剂组之间在疼痛缓解方面观察到具有统计学意义的差异（P≤0.001）。同样，在治疗后1小时（48.2%对28.0%；P≤0.005）、2小时（61.2%对40.0%；P≤0.005）、3小时（68.2%对44.0%；P≤0.001）、4小时（67.9%对39.0%；P≤0.001）和6小时（64.3%对37.0%；P≤0.001），报告生活质量改善的患者比例显著更高。平均疼痛强度和生活质量得分降低，而相对疼痛强度和生活质量（AAC组与安慰剂组之间的差异）随时间增加并持续6小时。AAC的快速起效和持续作用使其成为治疗头痛和其他症状以及改善MM患者生活质量的一个潜在选择。
